Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Essential thrombocythemia (ET) is a BCL-ABL1-negative myeloproliferative neoplasm.
|
28415571 |
2017 |
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The classical BCR-ABL1-negative myeloproliferative neoplasms (MPN) include primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET).
|
29134817 |
2017 |
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparative genomic hybridization (CGH), using oligo arrays with either 44,000 or 105,000 oligonucleotides, was performed on granulocyte-derived DNA from 71 patients with BCR-ABL-negative classic myeloproliferative neoplasms (MPNs): 32 primary myelofibrosis (PMF), 26 polycythemia vera (PV) and 13 essential thrombocythemia (ET).
|
18937974 |
2009 |
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The classical BCR-ABL1-negative myeloproliferative neoplasms (MPN) include essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).
|
26933174 |
2016 |
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chronic myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells, which fall into distinct categories based on a number of characteristics including the presence of the BCR-ABL1 gene fusion (chronic myelogenous leukemia) or the JAK2(V617F) mutation (polycythemia vera, primary myelofibrosis, and essential thrombocythemia).
|
22847163 |
2012 |
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The current study reported cases of two patients with an initial diagnosis of ET in the presence of JAK2V617F mutation and BCR‑ABL translocation by fluorescent in situ hybridization.
|
29845291 |
2018 |
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
|
28406068 |
2017 |
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chromosomal deletions of band 13q14 occur recurrently in BCR/ABL negative chronic myeloproliferative disorders (CMPD), including myelosclerosis with myeloid metaplasia (MMM), polycythemia vera (PV), essential thrombocythemia (ET), juvenile chronic myeloid leukemia (JCML), and the so-called BCR/ABL- chronic myeloid leukemia (CML).
|
8527391 |
1995 |
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polycythaemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (MF), are the most common myeloproliferative neoplasms (MPN) in patients without the BCR-ABL1 gene rearrangement.
|
23986553 |
2014 |
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of BCR-ABL1 is critical in the distinction of ET from CML.
|
26754830 |
2016 |
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results confirm the absence of BCR-ABL abnormalities in Ph-negative ET patients.
|
11342314 |
2000 |
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Myeloproliferative neoplasms (MPN) that do not contain the BCR-ABL1 mutation include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
|
22035746 |
2011 |
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCR-ABL positive essential thrombocythaemia: a variant of chronic myelogerous leukaemia or a distinct clinical entity: a special case report.
|
11296785 |
2000 |
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
With PCR, we looked for BCR/ABL transcripts in 30 patients with CML and 4 with essential thrombocythaemia at time of diagnosis, finding a significant difference in the platelet counts of CML patients carrying b3a2 or b2a2 transcripts.
|
7718325 |
1995 |
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia.
|
2065312 |
1991 |
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conclude that it is important to look for BCR-ABL transcript in Ph-neg ET patients and to follow them closely to investigate the nature of this translocation in this group of patients.
|
9326244 |
1997 |
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most affected patients suffer from the classic BCR/ABL1-negative myeloproliferative disorders (MPD), especially polycythemia vera (74% of n = 506), but a subset of people with essential thrombocythemia (36% of n = 339) or myelofibrosis with myeloid metaplasia (44% of n = 127) bear the identical mutation, as do a few individuals with myelodysplastic syndromes or an atypical myeloid disorder (7% of n = 556).
|
16321848 |
2006 |
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnosis and management of the BCR-ABL-negative myeloproliferative disorders (MPDs) of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are at an explosive crossroads of scientific investigation and evolving paradigms since the discovery of the tyrosine kinase-activating JAK2V617F mutation in 2005.
|
18024651 |
2007 |
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic lesions such as JAK2 mutations and BCR-ABL translocation are often mutually exclusive in MPN patients and lead to essential thrombocythemia, polycythemia vera, or myelofibrosis or chronic myeloid leukemia, respectively.
|
28335073 |
2017 |
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hence, we examined a cohort of 123 myeloproliferative neoplasm (MPN) patients without BCR-ABL1 rearrangement and additional ET patients (n=96) for coexistence of JAK2 and CALR mutations.
|
27486987 |
2016 |
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm diagnosed de novo or developed from essential thrombocythemia (ET) or polycythemia vera (PV).
|
22793267 |
2013 |
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that chromosome 1 abnormalities are most frequent in BCR-ABL-negative classic myeloproliferative neoplasms (MPN): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
|
20002154 |
2010 |
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Essential thrombocythemia with BCR/ABL rearrangement.
|
8689617 |
1996 |
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BCR/ABL-negative myeloproliferative neoplasms (MPNs) of essential thrombocythemia, polycythemia vera, and primary myelofibrosis, over the natural course of their disease, have an increasing predisposition to transform to overt acute myeloid leukemia (AML)-most appropriately referred to as MPN-blast phase (MPN-BP).
|
22170483 |
2012 |
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ROC curve analysis showed that a level of WT1 transcript >10 WT1 copies/10<sup>4</sup>ABL1 enabled the diagnosis of PMF with a specificity of 95.8% (PMF vs ET; ROC AUC = 0.91).
|
30612065 |
2019 |